BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 20471293)

  • 1. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
    Zeng H; Zhang H
    J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1.
    AbdulHameed MD; Hamza A; Liu J; Zhan CG
    J Chem Inf Model; 2008 Sep; 48(9):1760-72. PubMed ID: 18717540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined 3D-QSAR modeling and molecular docking study on quinoline derivatives as inhibitors of P-selectin.
    Zeng H; Cao R; Zhang H
    Chem Biol Drug Des; 2009 Dec; 74(6):596-610. PubMed ID: 19843078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
    Du J; Lei B; Qin J; Liu H; Yao X
    J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
    Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
    Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacophore and docking-based combined in-silico study of KDR inhibitors.
    Pasha FA; Muddassar M; Neaz MM; Cho SJ
    J Mol Graph Model; 2009 Aug; 28(1):54-61. PubMed ID: 19447057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors.
    Lan P; Chen WN; Xiao GK; Sun PH; Chen WM
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6764-72. PubMed ID: 20869873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family.
    Cao H; Zhang H; Zheng X; Gao D
    J Mol Graph Model; 2007 Jul; 26(1):236-45. PubMed ID: 17293140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular modeling studies of Rho kinase inhibitors using molecular docking and 3D-QSAR analysis.
    Qin J; Lei B; Xi L; Liu H; Yao X
    Eur J Med Chem; 2010 Jul; 45(7):2768-76. PubMed ID: 20347188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential choline kinase inhibitors: a molecular modeling study of bis-quinolinium compounds.
    Srivani P; Sastry GN
    J Mol Graph Model; 2009 Feb; 27(6):676-88. PubMed ID: 19147382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.
    Xu Y; Liu H; Niu C; Luo C; Luo X; Shen J; Chen K; Jiang H
    Bioorg Med Chem; 2004 Dec; 12(23):6193-208. PubMed ID: 15519163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
    Pandey G; Saxena AK
    J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
    Ravindra GK; Achaiah G; Sastry GN
    Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
    Yi P; Fang X; Qiu M
    Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling studies on imidazo[4,5-b]pyridine derivatives as Aurora A kinase inhibitors using 3D-QSAR and docking approaches.
    Lan P; Chen WN; Chen WM
    Eur J Med Chem; 2011 Jan; 46(1):77-94. PubMed ID: 21093113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidating inhibitory models of the inhibitors of epidermal growth factor receptor by docking and 3D-QSAR.
    Chen G; Luo X; Zhu W; Luo C; Liu H; Puah CM; Chen K; Jiang H
    Bioorg Med Chem; 2004 May; 12(9):2409-17. PubMed ID: 15080937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the structure-activity and structure-selectivity correlation of cyclic guanine derivatives as phosphodiesterase-5 inhibitors by molecular docking, CoMFA and CoMSIA analyses.
    Yang GF; Lu HT; Xiong Y; Zhan CG
    Bioorg Med Chem; 2006 Mar; 14(5):1462-73. PubMed ID: 16263288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docking, 3D-QSAR studies and in silico ADME prediction on c-Src tyrosine kinase inhibitors.
    Tintori C; Magnani M; Schenone S; Botta M
    Eur J Med Chem; 2009 Mar; 44(3):990-1000. PubMed ID: 18722033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.